Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test

Moderna shares more than doubled Wednesday after it announced initial results from a study of an experimental cancer treatment that would be the first of its kind if approved by regulators. Moderna and Merck are developing a treatment using an mRNA-based cancer vaccine called intismeran that is des...

Redirecting to full article...